Implementing an electronic end-of-life chemotherapy utilization measure Published March 2020 Citation Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ. . Journal of Oncology Practice. . http://ascopubs.org/doi/abs/10.1200/JOP.18.00408 Authors:Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ Sources:Journal of Oncology Practice Share Posted inPublicationsTreatment patterns More publicationsBlood NeoplasiaApril 2026Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimensPrescott J, Parrinello C, Sawas A, et al.Publication summaryPublicationsTreatment patternsChronic lymphocytic leukemiaISPORApril 2026Real-world (RW) treatment patterns and outcomes in patients with =2 lines of therapy (LOTS) for recurrent or progressive endometrial cancerBhak R, Iyer NN, Hopkins A, et al.Publication summaryPublicationsTreatment patternsAdvanced endometrial cancerBlood and Lymphatic Cancer: Targets and TherapyMarch 2026Health disparities in acute myeloid leukemia patients undergoing treatment with tyrosine kinase inhibitor (TKI) therapy targeting FLT3, IDH1, or IDH2Espinoza-Gutarra M, Jarrett B, Wang X, Afghahi A, Bae S. Publication summaryPublicationsHealth equityTreatment patternsAcute myeloid leukemia